Menu
Back to Journals » Drug Design, Development and Therapy » Volume 15
Review
Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 8,485 | Dovepress* | 6,571+ | 860 | 7,431 | |
| PubMed Central* | 1,914 | 453 | 2,367 | ||
| Totals | 8,485 | 1,313 | 9,798 | ||
| *Since 2 March 2021 | |||||
| Total mentioned | Delicious | Others | |||
|---|---|---|---|---|---|
| 9 | 0 | 0 | 1 | 3 | 5 |
View citations on PubMed Central and Google Scholar